The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

A Big Data Stumble in Healthcare

Posted by Brian Overstreet on February 24, 2017

This week marked the annual HIMSS Conference.  HIMSS, Healthcare Information and Management Systems Society, is the big annual gathering of IT firms trying to market their wares into healthcare systems, pharmaceutical companies, and health insurers.

While usually a time for big partnerships, acquisitions, deployments, and new client wins, this year’s HIMSS kicked off in a rather inglorious manner.  On Sunday news broke that world-renowned cancer center MD Anderson had discontinued their partnership with IBM Watson.  After a string of big wins by the Watson team, this appeared to be the first – and certainly the largest – setback.

Read More

Topics: Big Data

Guest Post: BBK Talks #BigData with Advera Health Analytics

Posted by Brian Overstreet on July 15, 2016

This post was originally published on the BBK Worldwide Blog.

Big Data was a Big Topic at this year’s DIA Annual Meeting, and continues to be an area of interest and investment across the life sciences and healthcare industries as organizations seek to further integrate new data streams and real-time analysis into clinical R&D. Data collection, management and analysis are at the crux of everything we do here at BBK, and our clients are keenly interested in how to manage and optimize Big Data. We interviewed Brian Overstreet, CEO of Advera Health Analytics, a leading healthcare informatics company, to get their take and to see how access to meaningful data is helping to push healthcare forward. 

Read More

Topics: Big Data, patient safety

Watson Health is the Ultimate Data Parasite

Posted by Jim Davis on March 3, 2016

One year after its birth, the ultimate data parasite has come of age by latching on to a $3 billion host. It is big, blue, pretty good at Jeopardy, and if you were to believe the data detractors, utterly useless.

Read More

Topics: Big Data, FAERS, Evidence

Fear of Lost Privacy Costs Lives

Posted by Brian Overstreet on February 2, 2016

Thursday January 28th was Data Privacy Day.  As the scale and scope of healthcare data grows, the importance of protecting patients’ privacy and ownership over their data will be a challenge for our community in the years ahead.  To honor the spirit of Data Privacy Day, we’re pleased to present a blog post below from our friends Joy Hwang and Peter Levin of Amida Technology Solutions.

Read More

Topics: Big Data, transparency

Big Data, Technology, and the New Health Economy

Posted by Brian Overstreet on January 8, 2016

This article originally appeared in Becker's Health IT & CIO Review on December 14, 2015. You can access the original article here

Read More

Topics: Big Data

Data Is Everything… Or Is It? Why Data Management Matters

Posted by Brian Overstreet on January 7, 2016

On Wednesday, Jan. 6, Forbes ran an article detailing a 7% drop in the price of Regeneron’s (REGN) stock price.  The company attributed that decline to investors obtaining data from the FDA Adverse Events Reporting System (FAERS) showing eight suicide cases from patient’s taking Regeneron’s new PCSK9 inhibitor Praluent (alirocumab).

The issue, of course, was that the people who obtained those data knew nothing about FAERS or its myriad problems with case duplications, incomplete records, or how to value reports submitted with multiple drugs and/or from dubious sources.

Read More

Topics: Big Data, FAERS, FOIA, Praluent, Regeneron, PCSK9

Applying Broken Windows Policing Theory to Drug Safety

Posted by Jim Davis on August 21, 2014

I read an interesting opinion piece in the Wall Street Journal recently titled Of Ferguson and Fallujah. In his essay Bret Stephens (@StephensWSJ) intends to compare President Obama’s foreign policy to the police response to the extremely unfortunate events that have been, and continue to be unfolding in Ferguson, MO. His view is that both are “disastrously reactive”.

To support his opinion, he uses the broken windows theory. Developed by George Kelling and James Q. Wilson, and written about in a 1982 Atlantic Monthly article. The title comes from the following example:

Read More

Topics: Big Data, Drug Formulary

Quiz: What Type of Drug Safety Professional Are You?

Posted by Jim Davis on July 31, 2014

Our business development team talks with healthcare decision makers all day, every day. They discuss medication safety best practices. They talk about utilizing data and analytics to make evidence based decisions. They teach on how post approval side effect data can be properly utilized in Formulary and P&T decisions, as well as how to use the data to better react to FDA trigger events. And sometimes, they just get hung up on.

Read More

Topics: Big Data, drug safety professionals

How many links does it take to get to the center of an FDA FOIA request?

Posted by Andrea Demakas on July 24, 2014

A Day in the Life of a Data Minion

Ever wonder what magic is happening behind the scenes at AdverseEvents? What goes into the process of data management before it shows up in your inbox, or you receive an email alert about breaking news in pharmacovigilance with data supplied by your favorite drug safety information specialists? Well, there’s a lot. And although it is not all glamorous, we tend to have fun doing it.

Read More

Topics: Big Data, FOIA, AdverseEvents, Inc, faers data

OpenFDA – the Good, the Bad, and the Ugly

Posted by Brian Overstreet on July 18, 2014

On June 3rd, the FDA launched OpenFDA, in an attempt to take large internal datasets and make them more accessible and usable by the developer and business community.

OpenFDA is delivered in a search-based API that should enable software developers to more easily build applications based on adverse event data from the FDA Adverse Event Reporting System (FAERS) dataset for the period 1/1/2004 to 6/30/3013. The FDA has announced plans to add device and food adverse events data to the framework, along with structured product labeling and recall data (update: drug and device recall data was added on July 16). 

The launch was heralded with the sort of buzz and hoopla usually reserved for a major product launch from a Silicon Valley startup. I decided to hold off on any analysis and opinion until now to give our team the needed time to look through the system thoroughly.

Read More

Topics: Big Data, FAERS, OpenFDA

Subscribe to Email Updates